# A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

> **NCT00652366** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 467 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Erlotinib, escalating dose
- **DRUG:** Erlotinib, standard dose
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00652366
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2015-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00652366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00652366, "A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00652366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*